Answers are grounded in this paper and cite their sources.
The study was devoted to the evaluation of dose-dependent efficacy of N-acetylglucosamine and quercetin combination in the treatment of renal failure. The combination was studied in injectable dosage form at the doses of 10, 20, 40 and 60 mg/kg in rats with chromium-induced nephropathy. The efficacy of combination was assessed by animal survival, renal excretory function, nitrogen metabolism and nephroprotective activity. Also, the ED 50 index was calculated by Probit Analysis method. The efficacy of combination at doses of 40 and 60 mg/kg was most expressed with insignificant differences (p>0.05) between them. There was a significance increase (p<0.05) in animal survival, renal excretory function and normalization of nitrogen metabolism. This led to the nephroprotective activity of 67.8 and 70.4%, respectively. The ED 50 index of combination was 30.2 6.3 mg/ kg. Thus, this test combination at a dose of 30.2 mg/kg is the promising drug for experimental treatment of kidney diseases.
No takes yet. Share an insight, caveat, or question.
Шебеко et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: